相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer
Yuan-ming He et al.
ACTA PHARMACOLOGICA SINICA (2022)
Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease
Dawid Mehlich et al.
CANCER LETTERS (2022)
Combined Use of Immunoreactivities of RIG-I with Efp/TRIM25 for Predicting Prognosis of Patients With Estrogen Receptor-positive Breast Cancer
Junichiro Sato et al.
CLINICAL BREAST CANCER (2021)
HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3
Xuyang Hou et al.
CANCER MEDICINE (2021)
CDCA7 Facilitates Tumor Progression by Directly Regulating CCNA2 Expression in Esophageal Squamous Cell Carcinoma
Hongyi Li et al.
FRONTIERS IN ONCOLOGY (2021)
MiR-365a-3p-Mediated Regulation of HELLS/GLUT1 Axis Suppresses Aerobic Glycolysis and Gastric Cancer Growth
Rui Yang et al.
FRONTIERS IN ONCOLOGY (2021)
CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion
Carla Martin-Cortazar et al.
HAEMATOLOGICA (2020)
TRIM25 Promotes TNF-α-Induced NF-κB Activation through Potentiating the K63-Linked Ubiquitination of TRAF2
Yuchun Liu et al.
JOURNAL OF IMMUNOLOGY (2020)
TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway
Yanfeng Liu et al.
NATURE COMMUNICATIONS (2020)
Proliferation-associated long noncoding RNA,TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer
Yuichi Mitobe et al.
CANCER SCIENCE (2020)
CDCA7 and HELLS suppress DNA:RNA hybrid-associated DNA damage at pericentromeric repeats
Motoko Unoki et al.
SCIENTIFIC REPORTS (2020)
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
Lei Nie et al.
NATURE COMMUNICATIONS (2019)
CDCA7 and HELLS mutations undermine nonhomologous end joining in centromeric instability syndrome
Motoko Unoki et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer
Ken-ichi Takayama et al.
ONCOGENE (2018)
HELLS and CDCA7 comprise a bipartite nucleosome remodeling complex defective in ICF syndrome
Christopher Jenness et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer
Liping Ye et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
TRIM25 Binds RNA to Modulate Cellular Anti-viral Defense
Jacint G. Sanchez et al.
JOURNAL OF MOLECULAR BIOLOGY (2018)
Efp promotes in vitro and in vivo growth of endometrial cancer cells along with the activation of nuclear factor-κB signaling
Wataru Sato et al.
PLOS ONE (2018)
Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells
K. Tominaga et al.
ONCOGENE (2017)
An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis
Logan A. Walsh et al.
CELL REPORTS (2017)
RNA-binding activity of TRIM25 is mediated by its PRY/SPRY domain and is required for ubiquitination
Nila Roy Choudhury et al.
BMC BIOLOGY (2017)
Nuclear TRIM25 Specifically Targets Influenza Virus Ribonucleoproteins to Block the Onset of RNA Chain Elongation
Nicholas R. Meyerson et al.
CELL HOST & MICROBE (2017)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumor progression
Claudia A. Benavente et al.
ONCOTARGET (2014)
Trim25 Is an RNA-Specific Activator of Lin28a/TuT4-Mediated Uridylation
Nila Roy Choudhury et al.
CELL REPORTS (2014)
Oestrogen causes ATBF1 protein degradation through the oestrogen-responsive E3 ubiquitin ligase EFP
Xue-Yuan Dong et al.
BIOCHEMICAL JOURNAL (2012)
Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth
K. Ueyama et al.
CANCER GENE THERAPY (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Ligand-dependent transcription of estrogen receptor α is mediated by the ubiquitin ligase EFP
Ayako Nakajima et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity
Michaela U. Gack et al.
NATURE (2007)
JPO1/CDCA7, a novel transcription factor E2F1-induced protein, possesses intrinsic transcriptional regulator activity
Yuya Goto et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION (2006)
Estrogen-responsive finger protein as a new potential biornarker for breast cancer
T Suzuki et al.
CLINICAL CANCER RESEARCH (2005)
The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo
RC Osthus et al.
CANCER RESEARCH (2005)
Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth
T Urano et al.
NATURE (2002)
Identification of genes periodically expressed in the human cell cycle and their expression in tumors
ML Whitfield et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
Efp as a primary estrogen-responsive gene in human breast cancer
K Ikeda et al.
FEBS LETTERS (2000)
分享论文
